Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

72
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
72
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

43
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
43
Routes of Drug Administration: Parenteral01:25

Routes of Drug Administration: Parenteral

2.0K
The administration of drugs via parenteral routes allows for direct drug introduction into the systemic circulation, resulting in high bioavailability because the medication bypasses the harsh conditions of the gastrointestinal tract and hepatic metabolism.
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
2.0K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

225
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
225
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

17
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
17
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

773
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
773

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute kidney injury-epidemiology in intensive care unit patients 2: study protocol for a prospective international multicentre cohort study.

BMJ open·2026
Same author

Hyperlactatemia in sepsis and shock: a renal metabolic perspective.

Critical care (London, England)·2026
Same author

Ionized hypocalcemia prior to continuous veno-venous hemodialysis initiation: prevalence and consequences.

BMC anesthesiology·2026
Same author

CRRT and ECMO: one love or separate lives?

Intensive care medicine·2026
Same author

Metabolic complications of citrate anticoagulation in continuous renal replacement therapy (crrt): a delphi consensus on indications, monitoring and management.

Critical care (London, England)·2026
Same author

Clinical Performance in Critical Care Simulation Under Sleep Deprivation: Effects of Power Napping in the R-NAP Randomized Controlled Trial.

Anesthesiology·2026

Related Experiment Video

Updated: Jul 28, 2025

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.0K

Hemoperfusion: Indications, Dose, Prescription.

Frank Bidar1,2, Stanislas Abrard1,3, Antoine Lamblin1

  • 1Department of Anesthesiology and Critical Care Medicine, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.

Contributions to Nephrology
|June 1, 2023
PubMed
Summary
This summary is machine-generated.

Hemoperfusion (HP) uses advanced sorbent materials but lacks standardized protocols. Further research is needed to define optimal timing, dose, and duration for effective clinical application of HP therapies.

More Related Videos

Porcine Normothermic Isolated Liver Perfusion
08:41

Porcine Normothermic Isolated Liver Perfusion

Published on: June 9, 2023

937
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.5K

Related Experiment Videos

Last Updated: Jul 28, 2025

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.0K
Porcine Normothermic Isolated Liver Perfusion
08:41

Porcine Normothermic Isolated Liver Perfusion

Published on: June 9, 2023

937
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.5K

Area of Science:

  • Critical Care Medicine
  • Biomaterials Engineering
  • Nephrology

Background:

  • Sorbent materials have advanced hemoperfusion (HP) technology.
  • Current clinical practice guidelines lack consensus on HP dosing and prescription.
  • Standardized protocols are crucial for ensuring HP effectiveness.

Purpose of the Study:

  • To review the current status of hemoperfusion (HP) therapies.
  • To highlight the need for standardized protocols in HP.
  • To discuss potential applications and optimal operating conditions for HP devices.

Main Methods:

  • Review of recent advances in sorbent materials for hemoperfusion.
  • Analysis of current clinical practice regarding HP prescription and modality.
  • Examination of various HP devices (CytoSorb®, HA330/380, polymyxin B, Seraph®) and their applications.
  • Discussion of blood flow rates, session durations, and treatment frequencies.

Main Results:

  • Hemoperfusion (HP) devices are indicated for sepsis but show potential in liver failure, rhabdomyolysis, pancreatitis, and other critical conditions.
  • HP can be used as a standalone therapy or combined with renal replacement therapy.
  • Typical blood flow ranges from 100-700 mL/min, with varying session durations and repetition protocols for different devices.
  • Current clinical data are insufficient to establish optimal HP operating conditions.

Conclusions:

  • Optimal prescription and modality of hemoperfusion (HP) are critical for effectiveness.
  • Further studies are required to define optimal timing, dose, and duration for HP therapies.
  • Research defining optimal operating conditions will guide future clinical applications of hemoperfusion.